A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network

BACKGROUND: BI 2536, a novel Polo-like kinase 1 inhibitor, was assessed in patients with unresectable advanced exocrine adenocarcinoma of the pancreas. METHODS: The study employed a two-stage design. Randomised first-line patients received BI 2536 200 mg on day 1 (n=43) or 60 mg on days 1–3 (n=43) e...

Descripción completa

Detalles Bibliográficos
Autores principales: Mross, K, Dittrich, C, Aulitzky, W E, Strumberg, D, Schutte, J, Schmid, R M, Hollerbach, S, Merger, M, Munzert, G, Fleischer, F, Scheulen, M E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394983/
https://www.ncbi.nlm.nih.gov/pubmed/22699824
http://dx.doi.org/10.1038/bjc.2012.257

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394983/
https://www.ncbi.nlm.nih.gov/pubmed/22699824
http://dx.doi.org/10.1038/bjc.2012.257

Ejemplares similares